Digest Network Come funziona
Network
/
Società
Am
Non verificato

Amphista Therapeutics

Di cosa scriviamo

Annunci EconomiciBiotecnologiaPubblicità/Marketing/Media/Comunicazione

13 comunicati stampa

Guarda tutti i comunicati
26/02/2026
Biotecnologia
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys® platform is delivering Targeted Glue™ degraders using novel E3 ligases into the clinic
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
07/12/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
25/11/2025
Biotecnologia
Annunci Economici
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics announces new AMX-883 data to be presented at the ASH Annual Meeting and Exposition and provides a business progress update
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
28/10/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
27/10/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
23/10/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
15/10/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
23/09/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Annunci Economici
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
17/09/2025
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Amphista Therapeutics discloses first details of its SMARCA2 degrader program
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
16/07/2025
Biotecnologia
Annunci Economici
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
Fonte
Amphista Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0